Kazia Therapeutics (Kazia Therapeutics) EV-to-EBITDA

: -0.51 (As of Today)

View and export this data going back to 1999. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kazia Therapeutics's enterprise value is $7.63 Mil. Kazia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.00 Mil. Therefore, Kazia Therapeutics's EV-to-EBITDA for today is -0.51.

The historical rank and industry rank for Kazia Therapeutics's EV-to-EBITDA or its related term are showing as below:

KZIA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.38 Med: -4.65 Max: 4.77
Current: -0.51

During the past 13 years, the highest EV-to-EBITDA of Kazia Therapeutics was 4.77. The lowest was -34.38. And the median was -4.65.

KZIA's EV-to-EBITDA is ranked worse than
100% of 472 companies
in the Biotechnology industry
Industry Median: 9.005 vs KZIA: -0.51

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), Kazia Therapeutics's stock price is $0.369. Kazia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.757. Therefore, Kazia Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Kazia Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Kazia Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBITDA

Get a 7-Day Free Trial

-1.96

-3.12

-27.92

-3.29

-1.61

Kazia Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBITDA	Get a 7-Day Free Trial															-27.92	-	-3.29	-	-1.61

Competitive Comparison

For the Biotechnology subindustry, Kazia Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's EV-to-EBITDA falls into.

Kazia Therapeutics EV-to-EBITDA Calculation

Kazia Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	7.626	/	-14.997
	=	-0.51

Kazia Therapeutics's current Enterprise Value is $7.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kazia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.00 Mil.

Kazia Therapeutics (NAS:KZIA) EV-to-EBITDA Explanation

Kazia Therapeutics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.369	/	-0.757
	=	At Loss

Kazia Therapeutics's share price for today is $0.369.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kazia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.757.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Kazia Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Kazia Therapeutics (Kazia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000

Website

https://www.kaziatherapeutics.com

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Executives

Josiah T Austin	director, 10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc	10 percent owner	4673 CHRISTOPHER PLACE, DALLAS TX 75204